Navigation Links
Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
Date:10/28/2008

ts." Such statements include, but are not limited to, references to (i) the expected occurrence, timing and trial design of the planned development activities for ANA598, including Anadys' expectation that it will have viral load data from all three cohorts of the Phase Ib study in the first quarter of 2009; (ii) the expectation that the maximal benefit of direct antivirals will be realized when used in combination regimens incorporating multiple anti-HCV agents; (iii) the potential for once-daily or twice-daily oral dosing with ANA598; (iv) predictions of future antiviral activity of ANA598 based on plasma drug concentrations seen in the healthy volunteer study and preclinical results to date; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause ac
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Anadys Pharmaceuticals to Present at Bio Investor Forum
2. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
5. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
6. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
7. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
8. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
9. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
10. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
11. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/20/2014)... 2014 With a mere 19 days ... made a brief fundraising stop at the  Law ... Fresh from a debate last night with his opponent ... for the first seven minutes because Crist had an ... the incident in one word: "weird." , Before touching ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... Journal of Clinical Dentistry Demonstrate, Significant Cavity-Fighting ... N.Y. and STONY BROOK, N.Y., April 8, 2008 ... announced today that,new data published in the most ... the effects of a new chewable mint in ...
... Three-year demonstration project will test effectiveness of ... of chronic illness in the,Medicare population, ... Board: HFIT) announced today it is working ... of Pfizer Inc., as part of a,three-year ...
... Huckabee Share Behavior Change Successes ... and Discuss Healthcare Strategies and Trends, PALM SPRINGS, ... in scalable behavior change interventions with outcomes,kicked off ENGAGE ... 250 industry experts and leading employers and health plans,throughout ...
... be the greatest advance in waking up since coffee, ... wake up,in the morning feeling refreshed and ready to go, ... performance to spousal,relations and even driving ability. Fortunately, a unique ... a pill you take before,bedtime that will help you to ...
... 2008 Take a look in your,medicine cabinet ... so, are,you contributing to the nation,s dramatic increase ... National Drug Control,Strategies Report, 71 percent of prescription ... friends. Among 12- to 13-year-olds,prescription drug abuse actually ...
... The appearance of a cold sore is,a sign ... more serious,illnesses emerge, according to John Sherman, ND, noted ... Worldwide, between 80% and 90% of the adult population ... according to Dr. Sherman, who,is the author of The ...
Cached Medicine News:Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 2Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 3Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 4Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 3Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 4Health News:HealthMedia Kicks Off ENGAGE Conference 2Health News:HealthMedia Kicks Off ENGAGE Conference 3Health News:Tired Mother Invents Pill to Wake You Up On Time 2Health News:Prescription Drug Abuse Threatens Availability of Pain Medication 2Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation leader ... of the cQUB™-1 (cQuest Ultrasound Box™-1), the first product ... designed and manufactured by Cephasonics for purchase by companies ... number. Cephasonics will be showcasing the cQUB-1 for the ... week in Chongqing, China from ...
(Date:10/22/2014)... Oct 22, 2014 Antigen Discovery Inc. (ADi), ... , announced the receipt of a National Institutes ... (SBIR) from the National Institute of Dental and Craniofacial Research ... of a Pan-HIV Protein Microarray Chip, which will contain ... subtypes and aid in the development of safe and ...
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak Industries, ... developed APLS ® Body Guard Bio, a ... spread of bacteria and virus while protecting service ... Guard Bio features a rugged, external nylon shell, ... create a leak-proof inner chamber that contains contaminated ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... 2011 Reportlinker.com announces that a ... in its catalogue: ... and Roadmapping ... service profiles technology market penetration and ...
... June 20, 2011 Reportlinker.com ... research report is available in ... Transfusion Diagnostic Testing Market: US, ... Expansion Strategies for Suppliers ...
Cached Medicine Technology:Reportlinker Adds Endovascular Surgical Interventions: Technology Market Penetration and Roadmapping 2Reportlinker Adds Endovascular Surgical Interventions: Technology Market Penetration and Roadmapping 3Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 2Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 3Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 4Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 5Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 6Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 7Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 8Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 9Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 10Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 11Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 12Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 13Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 14Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 15Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 16Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 17Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 18Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 19Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers 20
... x 7.5 x 80 mm. Grooved buckle. Size: ... Storz offers the original Scleral Sponge II line ... material is a closed cell sponge which is ... edges to minimize scleral intrusion. These implants are ...
... 80 mm. Storz offers the original ... Harvey A. Lincoff, M.D. The material ... is non-toxic and non-antigenic. Implants are ... scleral intrusion. These implants are packaged ...
... x 80 mm. Half oval. The original Scleral ... M.D. has been modified by Dr. Joseph Olk ... a closed cell sponge which is non-toxic and ... minimize scleral intrusion. These implants are packaged sterile ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
Medicine Products: